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AbstrACt
Objective To evaluate the cost–utility of 100 days of 
antibiotics in patients with chronic low back pain (LBP) 
and type I or II Modic changes included in the Antibiotic 
treatment In patients with chronic low back pain and 
Modic changes (AIM) study.
Design A cost–utility analysis from a societal and 
healthcare perspective alongside a double- blinded, parallel 
group, placebo, multicentre trial.
setting Hospital outpatient clinics at six hospitals in 
Norway. The main results from the AIM study showed 
a small effect in back- related disability in favour of the 
antibiotics group, and slightly larger in those with type I 
Modic changes, but this effect was below the pre- defined 
threshold for clinically relevant effect.
Participants 180 patients with chronic LBP, previous disc 
herniation and Modic changes type I (n=118) or type II 
(n=62) were randomised to antibiotic treatment (n=89) or 
placebo- control (n=91).
Interventions Oral treatment with either 750 mg 
amoxicillin or placebo three times daily for 100 days.
Main outcome measures Quality- adjusted life years 
(QALYs) by EuroQoL- 5D over 12 months and costs for 
healthcare and productivity loss measured in Euro 
(€1=NOK 10), in the intention- to- treat population. Cost–
utility was expressed in incremental cost- effectiveness 
ratio (ICER).
results Mean (SD) total cost was €21 046 (20 105) 
in the amoxicillin group and €19 076 (19 356) in the 
placebo group, mean difference €1970 (95% CI; −3835 to 
7774). Cost per QALY gained was €24 625. In those with 
type I Modic changes, the amoxicillin group had higher 
healthcare consumption than the placebo group, resulting 
in €39 425 per QALY gained. Given these ICERs and a 
willingness- to- pay threshold of €27 500 (NOK 275 000), 
the probability of amoxicillin being cost- effective was 51%. 
Even when the willingness- to- pay threshold increased to 
€55 000, the probability of amoxicillin being cost- effective 
was never higher than 53%.
Conclusions Amoxicillin treatment showed no evidence 
of being cost- effective for people with chronic LBP and 
Modic changes during 1- year follow- up.
trial registration number  ClinicalTrials. gov 
NCT02323412.
IntrODuCtIOn
Low back pain (LBP) represents a major 
economic burden.1 2 In several western coun-
tries, the social and healthcare costs related 
to LBP are enormous.3–5 The economic 
burden of LBP can be compared with other 
high- cost conditions such as cardiovascular 
disease, cancer and mental disorders.6 LBP is 
the most common reason for seeking health-
care services in Norway,7 and chronic LBP 
strengths and limitations of this study
 ► This is the first cost–utility study of antibiotic treat-
ment versus placebo in patients with chronic low 
back pain and Modic changes.
 ► Amoxicillin treatment showed no evidence of being 
cost- effective during 1- year follow- up. This finding 
is in accordance with the main results of the AIM 
study.
 ► The majority of the total costs were due to produc-
tion loss; costs due to healthcare had only a minor 
impact.
 ► This health economy analysis used a placebo- 
control instead of usual care as a comparison group. 
However, the placebo group resembles usual care in 
previous studies from Norway.
 ► Costs related to adverse events and MRI were not 
directly assessed, but these were recorded indi-
rectly in the monthly registrations of healthcare 
consumption.
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is the major reason for sickness absence and disability 
pension.8 As in other Western countries, production 
loss accounts for the majority of costs due to LBP in 
Norway.3–5 8
The recent Lancet series claims that many of the 
procedures and treatments provided for LBP are low- 
value care.9 Low- value care is procedures and treat-
ments that provide little or no benefit to patients yet 
increase the cost of healthcare as well as social costs due 
to productivity loss. In order to reduce expenditure 
on low- value care for LBP and help decision- makers 
prioritise the allocation of scarce resources to high- 
value care, knowledge regarding the relative efficacy of 
treatments is necessary. Economic evaluations, in which 
the incremental effects and incremental costs of two or 
more interventions are compared, should be included 
when informing decision- makers about new treatment 
options for LBP.
Antibiotic treatment for chronic LBP with Modic 
changes was suggested as a radical new treatment option 
for these patients.10 Modic changes are signal changes 
in the vertebral bone marrow extending from the 
endplate11 and are classified into types I (oedema type), 
II (fatty type) and III (sclerotic type, less common).12 
Approximately 40%–50% of patients with non- specific 
LBP have Modic changes, but their clinical relevance is 
unclear.13 One hypothesis is that Modic changes and LBP 
may be due to a low- grade bacterial infection. A placebo 
controlled randomised trial10 reported substantial effect 
of 100 days of high- dosage antibiotic treatment on pain- 
related disability in patients with chronic LBP and type I 
Modic changes. The recent AIM replication study14 from 
Norway found a small, but not clinically important benefit 
of amoxicillin vs placebo on pain- related disability for 
patients with type I or type II Modic changes. In patients 
with type I Modic changes the benefit was slightly better, 
but still not clinically important.
The increasing number of published economic evalu-
ations of interventions for chronic LBP15 16 support the 
cost- effectiveness of guideline- endorsed treatments such 
as exercise, interdisciplinary rehabilitation, cognitive–be-
havioural therapy, acupuncture and spinal manipulation 
for people with sub- acute or chronic LBP. To our knowl-
edge, there is no cost- effectiveness analysis of treatments 
for chronic LBP with Modic changes. This type of analysis 
was not reported in the previous trial, but was included 
in the present AIM study. Therefore, the purpose of this 
study was to use AIM data to evaluate cost–utility during 
1- year follow- up of 100 days of antibiotics in patients with 
chronic LBP and type I or type II Modic changes. The 
specific research questions were:
1. What is the total cost per quality- adjusted life year 
(QALY) of providing 100 days of antibiotics compared 
to placebo in the total patient group during the inter-
vention period (baseline to week 13) and 1 year (base-
line to week 52)?
2. What is the total cost per QALYs in the subgroup of 
patients with type I Modic changes?
MethODs
study design, material and treatment
This study is a cost- effectiveness analysis embedded in 
the AIM study; a multicentre, randomised, double- blind, 
placebo- controlled, parallel- group trial with a treatment 
phase (100 days) and a follow- up phase (from day 101 
to day 365). The details of the AIM study design, recruit-
ment, randomisation, blinding and data collection are 
provided in the trial protocol17 and the report on clinical 
results.14Briefly, the trial was conducted at six hospitals 
across Norway. Patients were randomised to either amox-
icillin or placebo, stratified on Modic changes type (I/
II) and previous disc surgery with a 1:1:1:1 allocation and 
random block sizes of 4 and 6. The sample size was calcu-
lated to assess the treatment effect separately for type I 
and type II Modic changes subgroups.17
The patients were randomised to 100 days of oral treat-
ment with either 750 mg amoxicillin or placebo three 
times daily. All randomised patients started on the study 
medication and were included in the intention- to- treat 
(ITT) analysis. Patients were permitted to continue with 
their usual LBP therapy (eg, exercises, physiotherapy, 
analgesics) but were encouraged not to start additional 
treatments and to avoid non- steriodal anti- inflammatory 
drugs (NSAIDs). All adjunctive therapy was registered.
The trial was performed in accordance with the 
Declaration of Helsinki and the ICH- GCP (Good Clin-
ical Practice), and registered at  ClinicalTrials. gov in 
December 2014. Methods were unchanged after trial 
commencement.
treatment effect and utilities
To measure treatment effects and health utilities the 
EuroQoL 5D (EQ- 5D- 5L) utility index was used.18 The 
EQ- 5D- 5L is a generic and preference- weighted measure 
of health- related quality- of- life based on five dimensions: 
mobility, self- care, activities of daily life, pain and anxiety 
and/or depression. For each dimension, the patient 
assesses five possible levels of problems (from none to 
severe). The participants completed the EQ- 5D- 5L at 
baseline, after 100 days of treatment (week 13) and at 12 
month follow- up (week 52). Health gains were expressed 
as QALYs, which were derived from the EQ- 5D- 5L utility 
scores, using the UK tariff.19 A Norwegian tariff is not 
available. QALYs range from −0.59 to 1, where one corre-
sponds to perfect health, and −0.59 to worst imaginable 
health. Combining utility indexes and time, the QALYs 
were estimated as area under the curve using the trape-
zoidal method.20
The willingness- to- pay (WTP) threshold for LBP was 
based on the Norwegian governmental report No. 34 to 
the parliament with a value of NOK 275 000 (€27 500/
US$35 628) per QALY (Norwegian Ministry of Health 
and Care Services, 2016).21
Costs of healthcare and production loss
Healthcare utilisation, including medication, and work 
loss were reported each month throughout the whole 
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Table 1 Cost categories, units, valuation and unit price, all numbers in Euros and NOK for 2019






Direct costs of antibiotic 
treatment (amoxicillin 750 mg 
three times daily for 100 days)*
Per patient Cost 311.5 3115 NOMA price list, Imacillin TevaAmoksicillin 
-trihydrat, NOK 207.70 per 20 tbl a 750 
mg)22
Direct costs of placebo 
treatment (placebo three times 
daily for 100 days)
Per patient Cost 0 0 Not available at pharmacies, so the price set 
is 0. (The cost produced for this study was 
NOK 470.)
Non- opioid medication 
(NSAIDs:ibuprofen,paracetamol, 
other A- prescription medicines)
Per daily 
defined dose
Cost 1.6 16 Pharmacy selling price (over- the- counter)
Opioid medication (codein) Per daily 
defined dose
Cost 3.0 30 Pharmacy selling price
General practitioner* Per visit Cost 45.8 458 NOMA, general practitioner consultation
Medical specialist Per visit Cost 86 860 NOMA, specialist health service 
consultation (fee*2,+20 min)
Chiropractor Per visit Cost 50 500 Norsk Kiropraktorforening estimated 
average
Physiotherapist Per visit Cost 25 250 The Norwegian Physiotherapy Association, 
estimated average
Manual therapist Per visit Cost 41.9 419 The Norwegian Physiotherapy Association, 
estimated average
Psychomotoric physiotherapy Per visit Cost 41.9 419 The Norwegian Physiotherapy Association, 
estimated average
Acupuncture Per visit Cost 75 750 Average estimate from private price lists
Other therapists Per visit Cost 75 750 Average estimate from private price lists
Back surgery (fusion) Per surgery Cost 9621.4 96 214 DRG215B
Hospitalisations (non- surgery) Per day Cost 1140 11 400 DRG247 (/2) per patient
Rehabilitation stay (outpatient) Per day Cost 300 3000 UniCare price list, adjusted for health region 
authority supplements
Production loss (225 work days 
per year)*
Per day Wage rate 
adjusted 
for age and 
gender
246.3 2463 Statistics Norway8 23
*Costs varied in multiway sensitivity analysis (Tornado diagram): GP, other healthcare costs, production loss (−20 /+20%). The cost of 
antibiotic treatment varied −50%/+20%, as amoxicillin is a generic product and the price is expected to decrease in the future.
NOMA, Norwegian Medicines Agency; NSAID, non- steriodal anti- inflammatory drug.
study period in the web- based data capture system 
(Viedoc) that was used in the AIM study: during the treat-
ment period until first follow- up week 13, it was filled 
in by the treating doctor and from week 14 until week 
52 it was filled in by self- report of the participants. The 
registration included number of visits to a general prac-
titioner, medical specialist, physical therapist, manual 
therapist or other physical therapy specialist, and other 
therapists (specified); number of days of hospitalisation 
and/or rehabilitation; use of medication (both prescrip-
tion and over- the- counter medication) and type of medi-
cation (name of medication, dosage). The monthly 
registration also contained information about work loss 
which included work status in terms of working time 
(percentage of position), partial sick leave (percentage, 
duration and reason), complete sick leave (duration and 
reason), disability pension (percentage, duration and 
reason), unemployment (yes, no) and student/other/
unknown (yes, no). Use of healthcare due to adverse 
events was also registered. We did not assess distance and 
transportation related to the healthcare utilisation and, 
hence, could not calculate transportation costs.
Costs were estimated on a present- value basis of the Euro 
in 2019, using the exchange rate from 2019 (September: 
€1=NOK 10). Analysis included healthcare and societal 
perspectives, the latter including costs due to healthcare 
and productivity loss. Cost categories, units, valuation and 
unit price are presented in table 1. Costs for the antibi-
otic medication were valued using unit prices from the 
Norwegian Medicines Agency.22 Pharmacy Selling Price 
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was used (with VAT included). Costs due to other health-
care consumption related to LBP were estimated based 
on data from the monthly registrations. Number of days 
of sick leave due to LBP was calculated for each month 
and adjusted for part- time work (employment rate), as 
well as percentage sick leave in the period. The costs of 
productivity loss were estimated as the number of days 
absent from work multiplied by the average wage rate in 
Norway by sex. Costs for absence from work were esti-
mated from official statistics of average wage by sex and 
age groups,8 23 including social costs of 40% and adjusted 
for employment and sick leave rate.
statistical analysis
The baseline characteristics of intervention and control 
group participants were compared with those of partici-
pants with complete and incomplete data using descrip-
tive statistics. Student’s t- tests and corresponding 95% 
CIs were used to analyse differences in costs, and Anal-
ysis of Covariance (ANCOVA) was used to analyse differ-
ences in utilities with adjustment for baseline score, the 
six hospitals, physical workload and use of healthcare at 
baseline (which were unequally distributed across the two 
groups at baseline). An incremental cost- effectiveness 
ratio (ICER) was calculated, defined by the incremental 
costs (costs in the antibiotic group – costs in the placebo 
group) relative to QALYs gained (QALYs antibiotic group 
– QALYs placebo group). Differences between the two 
groups in QALYs gained were estimated using the trape-
zoidal method (the area under the curve combining utility 
indexes and time).20 Uncertainty was analysed using the 
bootstrap method with 10 000 replicated datasets.
To illustrate the statistical uncertainty surrounding 
ICERs, the bootstrapped cost and effect pairs were plotted 
on a cost- effectiveness plane (CE plane) with the ICERs 
on the y- axis and the incremental effects on the x- axis. 
The CE plane is divided into four quadrants; when the 
ICERs cluster in the south- east quadrant the intervention 
is less costly with an improved health gain (the interven-
tion is considered dominant over the comparator); the 
south- west quadrant reflects a less costly intervention but 
a worse health gain, whereas the north- east indicates a 
costlier intervention but with an improved health gain. 
This represents a ‘trade- off’ situation, in which increases 
in cost must be compared with improvements in health 
(north- east quadrant); assuming WTP for an additional 
QALY, one can see whether the treatment is cost- effective 
(under the cost- effectiveness WTP threshold) or not 
(if above WTP threshold). The north- west quadrant 
reflects a more costly intervention with a poorer health 
gain (the intervention is considered to be dominated by 
the comparator). Cost- effectiveness acceptability curves 
(CEAC) were used to demonstrate the probability that 
antibiotics are cost- effective in comparison to placebo for 
a range of different WTP values.
The ITT method was used. There were little missing 
data, and missing values were imputed with a multiple 
imputation model described in the published protocol.17 
To assess the robustness of the results, the following sensi-
tivity analyses were carried out:
1. Complete case analysis (without adjustment for miss-
ing data).
2. Without outliers (one patient who had surgery plus 
hospital stay, one patient with hospital stay (without 
surgery) and two patients with 3 weeks of rehabilita-
tion stay).
3. Uncertainty of the ICER was tested by bootstrapping 
with 10 000 repetitions (probabilistic sensitivity anal-
ysis).
4. In a multiple one- way sensitivity analysis, the relevant 
costs and QALYs were varied 20% below and above 
the estimate given in table 1. The cost of antibiotics 
was varied −50 %/+20% due to expected price de-
crease (generic medicine). Results are presented in a 
Tornado diagram showing the number of one- way sen-
sitivity analyses in one graph.
Patient and public involvement
A patient representative was a member of the Scientific 
Board of the study, which effected all the major decision 
from planning and design of the study, to the dissemi-
nation of the study results. The patient representative 
assessed the burden of the study medication and the 
time and efforts required to participate in the trial. We 
will disseminate the results to study participants and the 
patient organisation (Norwegian Back Pain Association) 
in advance of publication.
results
Patients
From June 2015 to September 2017, 180 patients (118 
with type I Modic changes and 62 with type II Modic 
changes) were randomised to receive amoxicillin (n=89) 
or placebo (n=91). Demographic and clinical character-
istics at baseline are shown in table 2. There were only 
minor differences between the two groups in baseline 
characteristics (age, gender, comorbidity, former disc 
surgery, Modic changes type, pain duration, pain inten-
sity, disability, quality- of- life and work status), whereas a 
slightly larger difference was found in the use of health-
care in the month prior to inclusion and in physical 
workload. Compared with the placebo group, patients 
receiving amoxicillin reported more use of healthcare 
and less physical workload.
Missing data
Three patients had incomplete data on any of the 
monthly registrations of healthcare consumption during 
the year of follow- up, whereas six lacked data on produc-
tivity loss. A total of eight patients had incomplete data in 
the EQ5D- 5L. Details of missing data are provided in the 
online supplementary appendix A.
Cost–utility
The costs in both groups during the intervention period 
and follow- up period are provided in table 3. Costs were 
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Table 2 Baseline characteristics of participants in the treatment groups and for those with type I MCs
Amoxicillin 
(n=89) Placebo (n=91)
Type I MCs 
amoxicillin
(n=60)
Type I MCs 
placebo
(n=58)
Age (mean (SD)) 44.7 (9.0) 45.2 (9.0) 46.0 (9.3) 44.9 (9.3)
Women 53 (60) 52 (57) 35 (58) 35 (60)
Smoking, yes 25 (28) 21 (24) 13 (22) 18 (31)
Previous disc surgery 18 (20) 20 (22) 12 (20) 10 (17)
Educational level
  Primary school (9 years) 10 (11) 9 (10) 4 (6.7) 8 (14)
  High school (12 years) 36 (41) 42 (47) 27 (45) 21 (36)
  College or university (<4 years) 27 (31) 18 (20) 11 (18) 17 (29)
  University (≥4 years) 15 (17) 20 (22) 16 (27) 11 (19)
Employment status
  Working full time 46 (52) 43 (47) 33 (57) 32 (53)
  Partial sick leave 14 (16) 20 (22) 7 (12) 11 (19)
  Complete sick leave 22 (25) 16 (18) 14 (24) 11 (19)
  Disability pension 3 (3) 7 (8) 3 (5) 2 (3)
  Unemployed 2 (2) 3 (3) 1 (2) 2 (3)
  Student/other/unknown 2 (2) 2 (2) 0 2 (3)
Physical workload
  Mostly sitting 37 (48) 26 (35) 18 (30) 28 (48)
  Job requires a lot of walking 20 (26) 20 (27) 14 (23) 12 (21)
  Job requires a lot of walking and lifting 17 (22) 24 (32) 13 (22) 9 (16)
  Job requires physically heavy work 3 (4) 4 (5) 4 (6.7) 2 (3.4)
Comorbidity*
  Score 1 (back pain only) 62 (70) 60 (66) 40 (67) 40 (69)
  Score 2 21 (24) 27 (30) 17 (28) 13 (22)
  Score >2 6 (7) 4 (4) 3 (5.0) 5 (8.6)
Use of healthcare in the month prior to inclusion 24 (27) 15 (17) 17 (29) 10 (17)
Use of medication the month prior to inclusion
  Non- opioid medication 46 (52) 52 (57) 30 (52) 34 (57)
  Opioid medication 28 (32) 26 (29) 17 (29) 10 (17)
Duration of back pain in years (median (IQR)) 3.0 (1.5–5.6) 3.4 (1.7–7) 4 (2–8) 2.8 (1.5–5.2)
Back pain intensity (0–10) 6.4 (1.2) 6.3 (1.5) 6.5 (1.1) 6.3 (1.3)
Roland- Morris Disability Questionnaire (0–24) 12.7 (4.7) 12.8 (3.7) 12.9 (4.3) 12.3 (3.7)
EQ- 5D- 5L (-0.59–1) 0.55 (0.19) 0.54 (0.18) 0.55 (0.18) 0.56 (0.16)
N refers to the number of patients providing data.
Values are no/total no (%) unless stated otherwise.
*Functional Comorbidity Index33 – Score increased by 1 for each 18 diagnoses associated with decreased physical function.
MC, Modic changes.
mainly related to productivity loss, accounting for 96% 
of the total costs in the amoxicillin group and 98% in 
the placebo group, amounting to €20 091 and €18 774, 
respectively. The mean healthcare costs were approx-
imately threefold in the amoxicillin group as in the 
placebo group during the follow- up year, with an average 
of €955 vs €302, respectively. The online supplemen-
tary appendix A and B provide more details regarding 
number of patients and type and frequency of health-
care consumption during follow- up. In particular, the use 
of physiotherapy and manual therapy was substantially 
higher in the amoxicillin group. The costs due to produc-
tion loss were more equally distributed across the two 
groups (table 3). In total, the sum of all costs was €1970 
higher in the amoxicillin group than in the placebo group 
(95% CI €−3835 to €7774) (table 4). In the subgroup 
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Table 4 Differences in mean costs (€) and utilities (QALYs) with 95% CI and ICER during the intervention period (week 0–13) 





Mean incremental cost per 
QALY gained (ICER†)
Healthcare‡
  Week 0–13 413 (266 to 561) 0.04 (−0.02 to 0.09)
  Total 0–52 652 (291 to 1014) 0.08 (0.02 to 0.14) 8150
Productivity loss‡
  Week 0–13 358 (−1307 to 2022) 0.04 (−0.02 to 0.09)
  Total 0–52 1317 (−4458 to 7093) 0.08 (0.02 to 0.14) 16 463
Total main analysis‡
  Week 0–13 771 (−900 to 2442) 0.04 (−0.02 to 0.09)
  Total 0–52 1970 (−3835 to 7774) 0.08 (0.02 to 0.14) 24 625
Healthcare, type I MCs§
  Week 0–13 439 (223 to 656) 0.05 (−0.01 to 0.12)
  Total 0–52 532 (220 to 843) 0.08 (0.01 to 0.15) 6650
Productivity loss, type I MCs§
  Week 0–13 1037 (−1019 to 3092) 0.05 (−0.01 to 0.12)
  Total 0–52 2623 (−4581 to 9826) 0.08 (0.01 to 0.15) 32 788
Total type I Modic changes§
  Week 0–13 1476 (−594 to 3545) 0.05 (−0.01 to 0.12)
  Total 0–52 3154 (−4083 to 10392) 0.08 (0.01 to 0.15) 39 425
Complete case analysis¶
  Week 0–13 872 (−845 to 2590) 0.05 (−0.01 to 0.10)
  Total 0–52 2129 (−3823 to 8082) 0.08 (0.02 to 0.14) 26 613
Without outliers**
  Week 0–13 792 (−907 to 2491) 0.04 (−0.02 to 0.09)
  Total 0–52 1838 (−4089 to 7765) 0.08 (0.02 to 0.14) 22 975
*QALYs based on EuroQol’s health- related quality of life measure (EQ- 5D- 5L) with scores from −0.59 to 1. Higher scores indicating better 
quality of life. Differences are adjusted for baseline scores, the six study sites and use of healthcare and workload prior to inclusion.
†ICER = (Costs Amoxicillin arm – Costs Placebo arm) / (QALY Amoxicillin arm – QALY Placebo arm).
‡Main analysis by intention- to- treat (n=180).
§Including only type I Modic changes (n=118).
¶Complete case analysis without adjustment for missing data (n=.
**Sensitivity analysis by excluding five outliers (n=175) (ID3002, ID3018, ID3019, ID3029, ID4015).
ICER, incremental cost- effectiveness ratio; QALY, quality- adjusted life year.
of patients with type I Modic changes the costs due to 
productivity loss and healthcare were slightly higher in 
the amoxicillin group with a mean difference in total 
costs of €3154 (95% CI €−4083 to €10 392) (table 4).
At 1- year follow- up, there was a statistically significant 
difference in QALYs in favour of the amoxicillin group 
of mean 0.08 (95% CI 0.02 to 0.14) (table 4). This 
mean difference of 0.08 was also found when analyses 
were repeated without adjustment for missing data and 
without outliers (table 4). The ICER for the main anal-
ysis was €24 621. In the subgroup of patients with type I 
Modic changes, the ICER was €39 427.
The cost- effectiveness plane (figure 1) displays the boot-
strapped total cost and the differences in QALYs gained 
between amoxicillin and placebo with a WTP threshold 
of €27 500. Samples are slightly skewed towards the right 
with a similar distribution in the northeast and southeast 
quadrants. Figure 2 shows the CEAC curve, which presents 
the probability that amoxicillin is cost- effective compared 
with placebo for a range of different WTP thresholds. At 
a willingness- to- pay threshold of €27 500, the probability 
of amoxicillin being cost- effective was 51%. Even when the 
WTP threshold was increased to €55 000, the probability of 
amoxicillin being cost- effective was never higher than 53%.
The multiple univariate sensitivity analyses showed that 
productivity loss had the highest impact on the ICER in 
both treatment arms (figure 3). Even altering the cost of 
amoxicillin to 50% below the current estimate did not 
affect the ICER significantly.
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Figure 1 Cost- effectiveness plane. Each dot (n=10 000) 
represents a bootstrapped incremental cost- effectiveness 
ratio. QALY, quality- adjusted life years; WTP, willingness- to- 
pay.
Figure 2 The cost- effectiveness acceptability curve.
Figure 3 Tornado diagram (number of one- way sensitivity 
analyses presented in one graph). ICER, incremental cost- 




This health economic evaluation showed that 100 days of 
amoxicillin treatment is unlikely to be cost- effective for 
patients with LBP and Modic changes. Over the 1- year 
study period, the cost- effectiveness ratio was €24 621 per 
QALY gained for the total group, including patients with 
type I and type II Modic changes. In the type I Modic 
changes subgroup, the ICER was €39 427 per QALY 
gained. The sensitivity analyses supported these findings. 
The probability of amoxicillin being cost- effective never 
exceeded 53%.
Our results support the main results from the AIM 
study which detected no clinically important benefit of 
amoxicillin compared to placebo during 12 months of 
follow- up.14 The present cost–utility analysis also extends 
the findings from the AIM study by demonstrating that 
the patients in the amoxicillin group used more health-
care than the placebo group. In particular, the use of phys-
iotherapy and manual therapy was substantially higher in 
the amoxicillin group. Both physiotherapy and manual 
therapy are found to affect pain and disability as well as 
health- related quality- of- life outcomes in chronic LBP.24 
Consequently, the differences observed in the EQ- 5D- 5L 
scores, and thus in the QALYs, might be an overestima-
tion of the true treatment effect of amoxicillin.
When considering the threshold value of the ICER, 
or society’s WTP for a QALY, it is important to acknowl-
edge the denominator of this ratio. A QALY gain of 0.05 
to 0.08, which was found in the present analyses, is only 
slightly higher than the average QALY gain of exercise 
therapy compared to usual care in subacute and chronic 
LBP.25 The QALY gained in the present study translates 
to approximately 3 weeks in best imaginable health.26 
Our findings are very similar to findings in a systematic 
review of all cost–utility analyses published in 2010; in 370 
studies the median incremental QALY gain (as mainly 
measured by the EQ5D- 3L) was 0.06.26 This review also 
found larger gains in studies in which the comparator was 
placebo or no- treatment. Despite the use of placebo as 
comparator in our study, we did not achieve larger QALY 
gains than 0.08.
Another important point to consider is the perspective 
of clinical importance of the QALY gained in the amox-
icillin group compared to the placebo group. According 
to a systematic review estimates for the QALY, minimal 
clinical important difference varies from 0.03 to 0.54 
with an average estimate of 0.18.27 Similarly, a Norwe-
gian study of patients with chronic LBP and degenera-
tive disc disease reported a minimal clinically important 
(within- group) change estimate for the EQ- 5D- 5L of 
0.17.28 Although the wide variation around mean values 
of QALY gains indicates that some individuals have larger 
gains than others, our findings are in line with the minor 
effects of most interventions for LBP. Two recent system-
atic reviews of health- economic effects of exercises26 and 
multidisciplinary rehabilitation29 for LBP, showed similar 
small estimates of QALYs gained but to different costs, 
depending on in which country the trial was conducted.
The suggested WTP threshold in Norway was NOK 275 
000 (€27 500) per QALY in 2016 for the lowest severity 
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grade patients.21 There is no consensus about the accept-
able maximum costs per QALY gained, but the Norwegian 
WTP threshold is quite similar to the National Institute 
for Health and Care Excellence (NICE) threshold (£20 
000–£30 000).30 The NICE threshold is commonly used 
to provide an indication of cost- effectiveness across inter-
national studies. Recent evidence indicates that the WTP 
threshold may vary depending on the severity and the prev-
alence of the disease.15 LBP is not generally a very serious 
disease, but it is prevalent and has a high impact on produc-
tivity loss and societal costs. Accordingly, more than 95% of 
the total costs in the present study were due to productivity 
loss.
limitations
A weakness of this health economy analysis is the use of a 
placebo instead of usual care as a comparison group. Due to 
the scarcity of resources, decision- makers have to compare 
different alternatives before deciding which one to fund. 
When a placebo is chosen as a comparator instead of active 
treatment, the level for determining the therapeutic and 
economic advantage might be lower. Studies using placebo 
or no- treatment as a comparator have shown larger QALY 
gains than studies using usual care as a comparator.26 
However, except for a request to avoid NSAIDs, both groups 
were permitted to continue with usual care. Therefore, we 
believe the use of healthcare in the placebo group resem-
bles usual care in Norway. In a previous study on patients 
with chronic LBP in which the control group received usual 
care, the 1- year mean healthcare costs, including primary 
and secondary care and medication, was approximately 
NOK 2000 per patient (2012- prices, equals approximately 
€200).31 This is similar to the mean healthcare costs during 
follow- up in our placebo group (€234 or NOK 2336 per 
patient).
Another limitation is that costs related to antibiotic resis-
tance were not included in these analyses. We did not specif-
ically record costs related to adverse events, but these were 
recorded indirectly in the monthly registrations of health-
care consumption. We did record the use of MRI and other 
imaging during the follow- up period. However, there were 
only minor differences between the groups with regard to 
medical specialist consultations and imaging (see online 
supplementary appendix A and B), and it is unlikely that 
their associated costs would influence the main results. The 
majority of the total costs in this study were due to produc-
tion loss; costs due to healthcare had only a minor impact.
Finally, a 1- year horizon was chosen for the present cost–
utility analysis since this study is an extension of the AIM 
Study. The cost–utility analysis might have been stronger if 
we modelled in a longer time horizon, for example, in a 
5- year time horizon. A longer time horizon has been found 
to increase QALY gains.26
Comparisons with other health-economic studies on chronic 
lbP
There is little evidence on cost–utility of medications 
for chronic LBP. Such evidence was neither found in 
two systematic reviews from 2011 in which trials with 
cost- effectiveness evaluations of guideline- endorsed treat-
ments16 and GP care15 for LBP were summarised, nor in 
the two recent systematic reviews of the health- economic 
effects of exercises25 and multidisciplinary rehabilitation29 
for LBP. To our knowledge, there is no cost- effectiveness 
or cost–utility study on pharmacotherapy for chronic LBP, 
with or without Modic changes. Hence, our results cannot 
be directly compared with other studies. In the scientific 
LBP literature, information on drug costs is often missing, 
and the general lack of high- quality economic evaluations 
in LBP has been thoroughly documented.32 The high 
economic burden of chronic LBP underlines the need 
for high- quality economic evaluations of new treatments, 
in particular those with a potential for side effects and 
safety issues. Antibiotics are a new treatment for chronic 
LBP, and there may be a risk of antibiotic resistance and 
other side effects. Since Modic changes are common in 
patients with chronic LBP,13 and since this is the first cost–
utility analysis of antibiotic treatment, we consider the 
present study to be important for researchers, clinicians 
and policy- makers.
COnClusIOns AnD POlICy IMPlICAtIOns
In conclusion, this cost–utility analysis on patients with 
chronic LBP and Modic changes has shown that amoxi-
cillin treatment is not cost- effective compared to placebo. 
The probability of amoxicillin being cost- effective was 
never higher than 53%, regardless of WTP. In the AIM 
study, in which this present analysis was embedded, amox-
icillin did not provide a clinically important benefit. Our 
findings give further support to the notion that amox-
icillin is not a cost- effective treatment for patients with 
LBP.
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